









Markets
/
Stocks
/
nasdaq-rigl
/

Rigel Pharmaceuticals Inc

RIGL

35.190USD

-0.930-2.57%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

638.49MMarket Cap

5.64P/E TTM



Rigel Pharmaceuticals Inc

35.190

-0.930-2.57%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rigel Pharmaceuticals Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rigel Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

36 / 159

Overall Ranking

98 / 4614

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

42.833

Target Price

+21.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Rigel Pharmaceuticals Inc Highlights

StrengthsRisks

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 49.10% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 5.55, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 14.42M shares, decreasing 6.04% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.55K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.39.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 8.75, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 69.46M, representing a year-over-year increase of 25.59%, while its net profit experienced a year-over-year increase of 124.62%.

Score

Industry at a Glance

Previous score

8.75

Change



Financials

8.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

Rigel Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 8.67, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 5.55, which is 341.81% below the recent high of 24.52 and 2106.36% above the recent low of -111.36.

Score

Industry at a Glance

Previous score

8.67

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 36/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 7.00, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for Rigel Pharmaceuticals Inc is 40.00, with a high of 69.00 and a low of 24.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 6 analysts

Buy

Current Rating

42.833

Target Price

+21.72%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Rigel Pharmaceuticals Inc

RIGL

Apple Inc

AAPL

GE Vernova Inc

GEV

Tapestry Inc

TPR

FMC Corp

FMC

Avantor Inc

AVTR

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 9.00, which is higher than the Pharmaceuticals industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 41.04 and the support level at 27.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.16

Change

-0.16

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

1.742

Buy

RSI(14)

60.302

Neutral

STOCH(KDJ)(9,3,3)

62.868

Neutral

ATR(14)

2.453

High Vlolatility

CCI(14)

113.357

Buy

Williams %R

38.066

Buy

TRIX(12,20)

0.336

Sell

StochRSI(14)

67.764

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

33.638

Buy

MA10

32.006

Buy

MA20

30.411

Buy

MA50

32.274

Buy

MA100

29.027

Buy

MA200

24.441

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 80.38%, representing a quarter-over-quarter increase of 1.33%. The largest institutional shareholder is The Vanguard, holding a total of 1.05M shares, representing 5.87% of shares outstanding, with 2.07% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

1.60M

+5.54%

Morgan Stanley & Co. LLC

1.48M

-0.07%

BlackRock Institutional Trust Company, N.A.

1.41M

-4.34%

The Vanguard Group, Inc.

Star Investors

1.05M

+2.41%

Soleus Capital Management, L.P.

658.14K

-41.79%

Acadian Asset Management LLC

623.00K

+10.26%

State Street Investment Management (US)

600.18K

-5.79%

Capitolis Liquid Global Markets LLC

591.55K

-14.65%

Geode Capital Management, L.L.C.

415.61K

+1.08%

Marshall Wace LLP

368.95K

+74.24%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 4.55, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.